| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| adalimumab spiegel | 1.6 | 0.6 | 6409 | 86 | 18 |
| adalimumab | 1.35 | 0.5 | 7323 | 69 | 10 |
| spiegel | 0.27 | 0.1 | 6221 | 75 | 7 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| adalimumab spiegel | 0.75 | 0.8 | 714 | 67 |
| adalimumab spiegelbestimmung | 0.46 | 0.9 | 9896 | 88 |
| adalimumab spiegel labor | 1.05 | 0.8 | 2975 | 90 |
Therapeutic drug monitoring (TDM) for adalimumab has a great potential for the management of anti TNF therapy. Studies have shown that targeting an adequate adalimumab trough level can support guidance of treatment in IBD patients.
How does adalimumab treat rheumatoid arthritis?Adalimumab is a type of drug known as a biological therapy. In rheumatoid arthritis (room-a-toyd arth-rye-tus) and some other conditions, too much of a protein called TNF is produced in the body. This causes inflammation, pain and damage to your joints. Anti-TNF drugs such as adalimumab block TNF and so reduce this inflammation.
What is the therapeutic window for adalimumab in IBD?Therapeutic drug monitoring (TDM) for adalimumab has a great potential for the management of anti TNF therapy. Studies have shown that targeting an adequate adalimumab trough level can support guidance of treatment in IBD patients. An optimal therapeutic window for trough levels seem to be the range from 5 to 12 µg/ml of adalimumab in serum.
What is adalimumab (Humira™)?Adalimumab (Humira™) is an anti-TNF drug. In rheumatoid arthritis and some other conditions, too much of a protein called TNF (tumour necrosis factor) is produced in the body, causing inflammation, pain and damage to the bones and joints.
